IL-7 Activators
The IL-7 activators represent a diverse group of chemicals that modulate the activity of IL-7, a cytokine crucial for lymphocyte development and survival. These chemicals exert their effects through specific biochemical pathways, intricately regulating IL-7 gene expression and signaling. SB203580, an inhibitor of p38 MAPK, indirectly activates IL-7 by disrupting the MAPK signaling pathway. This alteration enhances IL-7 gene transcription by affecting downstream transcription factors like ATF-2 and Elk-1. SP600125, a JNK inhibitor, indirectly activates IL-7 by disrupting the JNK signaling pathway, leading to changes in AP-1 transcription factor activity, known to regulate IL-7 gene expression. Additionally, SP2509, a BRD4 inhibitor, showcases how epigenetic modulation can indirectly activate IL-7. By inhibiting BRD4, SP2509 alters the chromatin landscape around the IL-7 gene locus, promoting increased transcription and subsequent IL-7 activation. CHIR99021, a GSK-3 inhibitor, indirectly activates IL-7 by activating Wnt signaling, which influences IL-7 gene expression through β-catenin-mediated transcriptional regulation.
S3I-201, a STAT3 inhibitor, indirectly activates IL-7 by disrupting IL-7 receptor-mediated intracellular signaling. By inhibiting STAT3, S3I-201 prevents negative feedback signaling, allowing sustained IL-7 receptor signaling and highlighting the role of STAT3 in IL-7 responsiveness. BAY 11-7082, an NF-κB inhibitor, indirectly activates IL-7 by modulating the NF-κB pathway, which impacts IL-7 gene expression. SPV106, an AMPK activator, indirectly activates IL-7 by influencing mTORC1-dependent signaling pathways linked to IL-7 gene regulation. SC144, an agonist of adenosine A2B receptor, indirectly activates IL-7 by stimulating cAMP/PKA signaling, influencing IL-7 gene regulation. Lastly, AS1517499, a VEGFR2 inhibitor, indirectly activates IL-7 by affecting angiogenesis-related pathways, modulating the microenvironment necessary for efficient IL-7 production. In conclusion, the IL-7 activators exemplify the intricate interplay between specific biochemical pathways and IL-7 regulation.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. Inhibition of p38 MAPK alters the MAPK signaling pathway, leading to increased IL-7 gene transcription. This is achieved by the inhibition of downstream transcription factors, such as ATF-2 and Elk-1, which regulate IL-7 expression. The modulation of this pathway by SB203580 results in enhanced IL-7 production, indirectly activating IL-7 signaling pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK (c-Jun N-terminal kinase) inhibitor. By inhibiting JNK, SP600125 disrupts the JNK signaling pathway, influencing AP-1 transcription factor activity. AP-1 is known to regulate IL-7 gene expression. Thus, SP600125 indirectly activates IL-7 by affecting the JNK/AP-1 pathway, leading to increased IL-7 production. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K (phosphoinositide 3-kinase) inhibitor. Inhibition of PI3K disrupts the PI3K/Akt signaling pathway, affecting downstream targets such as FOXO transcription factors. FOXO factors are involved in IL-7 gene regulation, and their inhibition by LY294002 can lead to increased IL-7 expression. Consequently, LY294002 indirectly activates IL-7 signaling by modulating the PI3K/Akt/FOXO pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is an irreversible inhibitor of PI3K. Inhibition of PI3K by Wortmannin disrupts the PI3K/Akt pathway, affecting the activity of FOXO transcription factors. FOXO factors play a role in IL-7 gene regulation, and their inhibition by Wortmannin can lead to increased IL-7 expression. Consequently, Wortmannin indirectly activates IL-7 signaling by modulating the PI3K/Akt/FOXO pathway, similar to the action of LY294002. | ||||||
SP2509 | 1423715-09-6 | sc-492604 | 5 mg | $284.00 | ||
SP2509 is a selective inhibitor of the BRD4 protein, a member of the BET family. BRD4 regulates transcriptional elongation by binding to acetylated histones. Inhibition of BRD4 by SP2509 alters the epigenetic landscape around the IL-7 gene locus, promoting increased transcription. This epigenetic modulation by SP2509 indirectly activates IL-7 by enhancing gene expression, showcasing the interplay between chromatin structure and IL-7 regulation. | ||||||
GSK-3 Inhibitor XVI | 252917-06-9 | sc-221691 sc-221691A | 5 mg 25 mg | $180.00 $610.00 | 4 | |
CHIR99021 is a selective inhibitor of GSK-3 (glycogen synthase kinase-3). Inhibition of GSK-3 leads to the stabilization and nuclear translocation of β-catenin, a key player in the Wnt signaling pathway. β-catenin can interact with transcription factors like TCF/LEF, influencing IL-7 gene expression. CHIR99021, by activating Wnt signaling, indirectly activates IL-7 through the modulation of β-catenin-mediated transcriptional regulation. | ||||||
Stat3 Inhibitor VI, S3I-201 | 501919-59-1 | sc-204304 | 10 mg | $151.00 | 104 | |
S3I-201 is a STAT3 (signal transducer and activator of transcription 3) inhibitor. Inhibition of STAT3 by S3I-201 disrupts IL-7 signaling, as STAT3 is involved in IL-7 receptor-mediated intracellular signaling. By inhibiting STAT3, S3I-201 indirectly activates IL-7 by preventing negative feedback signaling and allowing sustained IL-7 receptor signaling. This highlights the importance of STAT3 in fine-tuning IL-7 responsiveness in cells. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082 is an inhibitor of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells). Inhibition of NF-κB by BAY 11-7082 influences the NF-κB signaling pathway, which can modulate IL-7 gene expression. NF-κB is known to regulate various cytokine genes, including IL-7. Therefore, BAY 11-7082 indirectly activates IL-7 by influencing the NF-κB pathway and its impact on IL-7 transcription. | ||||||